image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - IL
$ 16.275
-1.12 %
$ 18.6 B
Market Cap
-11.22
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one TEVA stock under the worst case scenario is HIDDEN Compared to the current market price of 16.3 USD, Teva Pharmaceutical Industries Limited is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one TEVA stock under the base case scenario is HIDDEN Compared to the current market price of 16.3 USD, Teva Pharmaceutical Industries Limited is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one TEVA stock under the best case scenario is HIDDEN Compared to the current market price of 16.3 USD, Teva Pharmaceutical Industries Limited is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
16.5 B REVENUE
4.40%
-303 M OPERATING INCOME
-69.98%
-1.96 B NET INCOME
-218.54%
1.25 B OPERATING CASH FLOW
-8.85%
792 M INVESTING CASH FLOW
-18.18%
-1.79 B FINANCING CASH FLOW
6.38%
4.23 B REVENUE
-2.38%
-29 M OPERATING INCOME
43.14%
-275 M NET INCOME
37.07%
575 M OPERATING CASH FLOW
-44.28%
202 M INVESTING CASH FLOW
-24.63%
-674 M FINANCING CASH FLOW
0.00%
Balance Sheet Teva Pharmaceutical Industries Limited
image
Current Assets 12.6 B
Cash & Short-Term Investments 3.3 B
Receivables 3.06 B
Other Current Assets 6.19 B
Non-Current Assets 26.8 B
Long-Term Investments 0
PP&E 4.95 B
Other Non-Current Assets 21.8 B
Current Liabilities 12.8 B
Accounts Payable 2.2 B
Short-Term Debt 1.78 B
Other Current Liabilities 8.81 B
Non-Current Liabilities 20.8 B
Long-Term Debt 16.3 B
Other Non-Current Liabilities 4.51 B
EFFICIENCY
Earnings Waterfall Teva Pharmaceutical Industries Limited
image
Revenue 16.5 B
Cost Of Revenue 8.48 B
Gross Profit 8.06 B
Operating Expenses 8.37 B
Operating Income -303 M
Other Expenses 1.66 B
Net Income -1.96 B
RATIOS
48.74% GROSS MARGIN
48.74%
-1.83% OPERATING MARGIN
-1.83%
-9.91% NET MARGIN
-9.91%
-30.50% ROE
-30.50%
-4.17% ROA
-4.17%
-1.63% ROIC
-1.63%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Teva Pharmaceutical Industries Limited
image
Net Income -1.96 B
Depreciation & Amortization 1.06 B
Capital Expenditures -498 M
Stock-Based Compensation 123 M
Change in Working Capital -435 M
Others 1.99 B
Free Cash Flow 749 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Teva Pharmaceutical Industries Limited
image
Wall Street analysts predict an average 1-year price target for TEVA of $23.2 , with forecasts ranging from a low of $20 to a high of $28 .
TEVA Lowest Price Target Wall Street Target
20 USD 22.89%
TEVA Average Price Target Wall Street Target
23.2 USD 42.86%
TEVA Highest Price Target Wall Street Target
28 USD 72.04%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.085 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Teva Pharmaceutical Industries Limited
image
Sold
0-3 MONTHS
10.5 M USD 3
3-6 MONTHS
327 K USD 1
6-9 MONTHS
11.8 M USD 4
9-12 MONTHS
5.23 M USD 8
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 weeks ago
Feb 18, 2025
Sell 1.28 M USD
Francis Richard D
President and CEO
- 75506
16.9478 USD
2 weeks ago
Feb 12, 2025
Sell 2.89 M USD
Sabag Mark
See "Remarks"
- 177626
16.2508 USD
2 months ago
Dec 20, 2024
Sell 6.29 M USD
MIGNONE ROBERTO
Director
- 286000
22.0071 USD
3 months ago
Nov 20, 2024
Sell 327 K USD
Fox Christine
EVP, Head of U.S. Commercial
- 19388
16.8705 USD
6 months ago
Aug 12, 2024
Sell 1.71 M USD
Daniell Richard
Exec. VP, European Commercial
- 98943
17.2973 USD
6 months ago
Aug 09, 2024
Sell 70.2 K USD
Grant Angus
EVP, Business Development
- 4065
17.28 USD
6 months ago
Aug 09, 2024
Sell 783 K USD
Hughes Eric A
See "Remarks"
- 45060
17.3762 USD
7 months ago
Aug 01, 2024
Sell 423 K USD
Hughes Eric A
See "Remarks"
- 24537
17.2507 USD
8 months ago
Jun 18, 2024
Sell 8.84 M USD
MIGNONE ROBERTO
Director
- 519000
17.03 USD
9 months ago
May 15, 2024
Sell 260 K USD
Weiss Amir
Chief Accounting Officer
- 15500
16.8011 USD
9 months ago
May 16, 2024
Sell 210 K USD
Weiss Amir
Chief Accounting Officer
- 12635
16.6503 USD
9 months ago
May 13, 2024
Sell 255 K USD
Conway Vikki L
See "Remarks"
- 15219
16.7427 USD
11 months ago
Mar 06, 2024
Sell 1.05 M USD
Kalif Eliyahu Sharon
EVP, Chief Financial Officer
- 77550
13.5154 USD
11 months ago
Mar 05, 2024
Sell 352 K USD
Daniell Richard
Exec. VP, European Commercial
- 26053
13.5154 USD
11 months ago
Mar 05, 2024
Sell 305 K USD
Daniell Richard
Exec. VP, European Commercial
- 22576
13.5154 USD
11 months ago
Mar 05, 2024
Sell 19.3 K USD
Conway Vikki L
See "Remarks"
- 1427
13.5154 USD
11 months ago
Mar 05, 2024
Sell 1.35 M USD
Sabag Mark
EVP, International Markets
- 100000
13.5209 USD
1 year ago
Mar 04, 2024
Sell 27.3 K USD
Conway Vikki L
See "Remarks"
- 2042
13.3733 USD
1 year ago
Mar 04, 2024
Sell 19.9 K USD
Conway Vikki L
See "Remarks"
- 1490
13.3733 USD
1 year ago
Mar 04, 2024
Sell 414 K USD
Francis Richard D
President and CEO
- 31061
13.3373 USD
1 year ago
Mar 04, 2024
Sell 447 K USD
Daniell Richard
Exec. VP, European Commercial
- 33512
13.3373 USD
1 year ago
Mar 04, 2024
Sell 107 K USD
Hughes Eric A
See "Remarks"
- 8045
13.3373 USD
1 year ago
Feb 28, 2024
Sell 129 K USD
Drape Eric
Executive VP Global Operations
- 9815
13.116 USD
1 year ago
Feb 28, 2024
Sell 270 K USD
Daniell Richard
Exec. VP, European Commercial
- 20599
13.116 USD
1 year ago
Feb 28, 2024
Sell 17.9 K USD
Conway Vikki L
See "Remarks"
- 1366
13.116 USD
1 year ago
Feb 16, 2024
Sell 2.26 M USD
Drape Eric
Executive VP Global Operations
- 173261
13.0549 USD
1 year ago
Feb 15, 2024
Sell 980 K USD
Francis Richard D
President and CEO
- 74530
13.1514 USD
1 year ago
Feb 01, 2024
Sell 393 K USD
Weiss Amir
Chief Accounting Officer
- 31766
12.3703 USD
1 year ago
Aug 07, 2023
Sell 342 K USD
Kalif Eliyahu Sharon
EVP, Chief Financial Officer
- 35125
9.7335 USD
1 year ago
Aug 04, 2023
Sell 19.7 K USD
Weiss Amir
Chief Accounting Officer
- 1981.41
9.921 USD
1 year ago
Aug 01, 2023
Sell 438 K USD
Hughes Eric A
See "Remarks"
- 52742
8.2987 USD
1 year ago
Mar 06, 2023
Sell 164 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 16491
9.9309 USD
1 year ago
Mar 07, 2023
Sell 466 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 49475
9.4279 USD
1 year ago
Mar 06, 2023
Sell 15.6 K USD
Drape Eric
Executive VP Global Operations
- 1566
9.9309 USD
1 year ago
Mar 07, 2023
Sell 44.3 K USD
Drape Eric
Executive VP Global Operations
- 4699
9.4279 USD
1 year ago
Mar 06, 2023
Sell 192 K USD
Dethlefs Sven
EVP, North America Commercial
- 19355
9.9309 USD
1 year ago
Mar 07, 2023
Sell 547 K USD
Dethlefs Sven
EVP, North America Commercial
- 58066
9.4279 USD
1 year ago
Mar 06, 2023
Sell 179 K USD
Daniell Richard
Exec. VP, European Commercial
- 18002
9.9309 USD
1 year ago
Mar 07, 2023
Sell 509 K USD
Daniell Richard
Exec. VP, European Commercial
- 54007
9.4279 USD
2 years ago
Feb 28, 2023
Sell 444 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 44953
9.8866 USD
2 years ago
Feb 28, 2023
Sell 236 K USD
Drape Eric
Executive VP Global Operations
- 23888
9.8866 USD
2 years ago
Feb 28, 2023
Sell 96.9 K USD
Drape Eric
Executive VP Global Operations
- 9797
9.8866 USD
2 years ago
Feb 28, 2023
Sell 418 K USD
Dethlefs Sven
EVP, North America Commercial
- 42309
9.8866 USD
2 years ago
Feb 28, 2023
Sell 234 K USD
Daniell Richard
Exec. VP, European Commercial
- 23654
9.8866 USD
2 years ago
Feb 28, 2023
Sell 204 K USD
Daniell Richard
Exec. VP, European Commercial
- 20598
9.8866 USD
2 years ago
Aug 22, 2022
Sell 559 K USD
Kalif Eliyahu Sharon
EVP, Chief Financial Officer
- 55500
10.0666 USD
2 years ago
Jul 28, 2022
Sell 526 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 58163
9.0365 USD
2 years ago
May 17, 2022
Sell 1.07 M USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 130000
8.2159 USD
3 years ago
Mar 04, 2022
Sell 66.7 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 9057
7.3667 USD
3 years ago
Mar 04, 2022
Sell 46.7 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 6246
7.4825 USD
3 years ago
Mar 04, 2022
Sell 127 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 17008
7.4825 USD
3 years ago
Mar 04, 2022
Sell 65.9 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 8941
7.3667 USD
3 years ago
Mar 04, 2022
Sell 49.5 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 6618
7.4825 USD
3 years ago
Mar 04, 2022
Sell 135 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 18020
7.4825 USD
3 years ago
Mar 04, 2022
Sell 128 K USD
Drape Eric
Executive VP Global Operations
- 17157
7.4825 USD
3 years ago
Mar 04, 2022
Sell 29.2 K USD
Dethlefs Sven
EVP, North America Commercial
- 3904
7.4825 USD
2 years ago
Mar 07, 2022
Sell 166 K USD
Daniell Richard
Exec. VP, European Commercial
- 22576
7.3667 USD
3 years ago
Mar 04, 2022
Sell 153 K USD
Daniell Richard
Exec. VP, European Commercial
- 20456
7.4825 USD
3 years ago
Mar 04, 2022
Sell 119 K USD
Daniell Richard
Exec. VP, European Commercial
- 15920
7.4825 USD
3 years ago
Feb 28, 2022
Sell 52.5 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 6452
8.1422 USD
3 years ago
Feb 28, 2022
Sell 43.2 K USD
Shani Eli
EVP,Global Marketing&Portfolio
- 5311
8.1422 USD
3 years ago
Feb 28, 2022
Sell 61.8 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 7590
8.1422 USD
3 years ago
Feb 28, 2022
Sell 79.8 K USD
Drape Eric
Executive VP Global Operations
- 9797
8.1422 USD
3 years ago
Feb 28, 2022
Sell 39.6 K USD
Dethlefs Sven
EVP, North America Commercial
- 4862
8.1422 USD
3 years ago
Feb 28, 2022
Sell 168 K USD
Daniell Richard
Exec. VP, European Commercial
- 20598
8.1422 USD
3 years ago
Feb 09, 2022
Sell 55.4 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 6110
9.0602 USD
3 years ago
Feb 09, 2022
Sell 55.4 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 6116
9.0602 USD
3 years ago
Feb 09, 2022
Sell 32.5 K USD
Drape Eric
Executive VP Global Operations
- 3583
9.0605 USD
3 years ago
Feb 09, 2022
Sell 37.5 K USD
Dethlefs Sven
EVP, North America Commercial
- 4138
9.0602 USD
3 years ago
Feb 09, 2022
Sell 119 K USD
Daniell Richard
Exec. VP, European Commercial
- 13135
9.0605 USD
3 years ago
Aug 10, 2021
Sell 506 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 50860
9.9493 USD
3 years ago
May 21, 2021
Sell 440 K USD
Drape Eric
Executive VP Global Operations
- 40000
11.008 USD
3 years ago
May 11, 2021
Sell 387 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 37884
10.2187 USD
3 years ago
May 11, 2021
Sell 195 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 19066
10.2187 USD
3 years ago
May 11, 2021
Sell 202 K USD
Drape Eric
Executive VP Global Operations
- 19804
10.2208 USD
3 years ago
Mar 16, 2021
Sell 1.43 M USD
Sabag Mark
See "Remarks" below
- 127244
11.2195 USD
4 years ago
Mar 04, 2021
Sell 147 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 13930
10.5661 USD
4 years ago
Mar 04, 2021
Sell 78.9 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 7469
10.5661 USD
4 years ago
Mar 04, 2021
Sell 7.59 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 703
10.8 USD
4 years ago
Mar 05, 2021
Sell 121 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 11436
10.5439 USD
4 years ago
Mar 04, 2021
Sell 137 K USD
Nazzi Gianfranco
EVP, International Markets
- 12935
10.5844 USD
4 years ago
Mar 04, 2021
Sell 101 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 9515
10.5661 USD
4 years ago
Mar 04, 2021
Sell 65.4 K USD
Drape Eric
Executive VP Global Operations
- 6183
10.5844 USD
4 years ago
Mar 04, 2021
Sell 63.5 K USD
Dethlefs Sven
EVP Global Marketing&Portfolio
- 6012
10.5661 USD
4 years ago
Mar 04, 2021
Sell 79.5 K USD
Daniell Richard
Exec. VP, European Commercial
- 7513
10.5844 USD
4 years ago
Mar 03, 2021
Sell 5.03 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 463
10.8626 USD
4 years ago
Mar 02, 2021
Sell 164 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 15085
10.8453 USD
4 years ago
Mar 03, 2021
Sell 15.2 K USD
Nazzi Gianfranco
EVP, International Markets
- 1400
10.8796 USD
4 years ago
Mar 02, 2021
Sell 541 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 50000
10.8178 USD
4 years ago
Mar 03, 2021
Sell 6.58 K USD
Dethlefs Sven
EVP Global Marketing&Portfolio
- 606
10.8626 USD
4 years ago
Mar 03, 2021
Sell 10.8 K USD
Daniell Richard
Exec. VP, European Commercial
- 993
10.8796 USD
4 years ago
Mar 01, 2021
Sell 200 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 18430
10.8308 USD
4 years ago
Mar 01, 2021
Sell 107 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 9849
10.8308 USD
4 years ago
Mar 01, 2021
Sell 691 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 63278
10.9256 USD
4 years ago
Mar 01, 2021
Sell 165 K USD
Nazzi Gianfranco
EVP, International Markets
- 15177
10.8509 USD
4 years ago
Mar 01, 2021
Sell 657 K USD
Nazzi Gianfranco
EVP, International Markets
- 60410.357
10.8796 USD
4 years ago
Mar 01, 2021
Sell 118 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 10912
10.8308 USD
4 years ago
Mar 01, 2021
Sell 106 K USD
Drape Eric
Executive VP Global Operations
- 9795
10.8509 USD
4 years ago
Mar 01, 2021
Sell 81.1 K USD
Dethlefs Sven
EVP Global Marketing&Portfolio
- 7486
10.8308 USD
4 years ago
Mar 01, 2021
Sell 224 K USD
Daniell Richard
Exec. VP, European Commercial
- 20598
10.8509 USD
4 years ago
Feb 16, 2021
Sell 43.7 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 3926
11.1229 USD
4 years ago
Feb 16, 2021
Sell 23.3 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 2098
11.1229 USD
4 years ago
Feb 16, 2021
Sell 23.1 K USD
Drape Eric
Executive VP Global Operations
- 2079
11.1281 USD
4 years ago
Feb 09, 2021
Sell 159 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 12538
12.6945 USD
4 years ago
Feb 09, 2021
Sell 670 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 52774
12.6945 USD
4 years ago
Feb 09, 2021
Sell 50.4 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 3974
12.6945 USD
4 years ago
Feb 09, 2021
Sell 212 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 16720
12.6945 USD
4 years ago
Feb 09, 2021
Sell 52.9 K USD
Nazzi Gianfranco
EVP, International Markets
- 4155
12.7209 USD
4 years ago
Feb 09, 2021
Sell 222 K USD
Nazzi Gianfranco
EVP, International Markets
- 17480
12.7209 USD
4 years ago
Feb 09, 2021
Sell 74.4 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 5857
12.6945 USD
4 years ago
Feb 09, 2021
Sell 300 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 23639
12.6945 USD
4 years ago
Feb 09, 2021
Sell 43.9 K USD
Drape Eric
Executive VP Global Operations
- 3452
12.7209 USD
4 years ago
Feb 09, 2021
Sell 185 K USD
Drape Eric
Executive VP Global Operations
- 14527
12.7209 USD
4 years ago
Feb 09, 2021
Sell 72.3 K USD
Dethlefs Sven
EVP Global Marketing&Portfolio
- 5695
12.6945 USD
4 years ago
Feb 09, 2021
Sell 304 K USD
Dethlefs Sven
EVP Global Marketing&Portfolio
- 23962
12.6945 USD
4 years ago
Feb 09, 2021
Sell 167 K USD
Daniell Richard
Exec. VP, European Commercial
- 13135
12.7209 USD
4 years ago
Feb 09, 2021
Sell 703 K USD
Daniell Richard
Exec. VP, European Commercial
- 55287
12.7209 USD
4 years ago
Sep 09, 2020
Sell 2.99 K USD
Daniell Richard
Exec. VP, European Commercial
- 333
8.9844 USD
4 years ago
Aug 11, 2020
Sell 34 K USD
Crane Rosemary A
Director
- 2860
11.9013 USD
4 years ago
Mar 17, 2020
Sell 6.76 K USD
Griffin Deborah A
Chief Accounting Officer
- 944
7.1635 USD
4 years ago
Mar 17, 2020
Sell 16.9 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 2359
7.1635 USD
4 years ago
Mar 17, 2020
Sell 3.37 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 470
7.1635 USD
4 years ago
Mar 17, 2020
Sell 2.47 K USD
Nazzi Gianfranco
EVP, International Markets
- 345
7.1714 USD
4 years ago
Mar 17, 2020
Sell 2.72 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 380
7.1635 USD
4 years ago
Mar 17, 2020
Sell 960 USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 134
7.1635 USD
4 years ago
Mar 17, 2020
Sell 4.42 K USD
Daniell Richard
Exec. VP, European Commercial
- 616
7.1714 USD
5 years ago
Mar 04, 2020
Sell 54 K USD
Griffin Deborah A
Chief Accounting Officer
- 4807
11.2294 USD
5 years ago
Mar 03, 2020
Sell 5.26 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 463
11.3658 USD
5 years ago
Mar 03, 2020
Sell 6.45 K USD
Nazzi Gianfranco
EVP, International Markets
- 548
11.7657 USD
5 years ago
Mar 03, 2020
Sell 11.7 K USD
Daniell Richard
Exec. VP, European Commercial
- 991
11.7657 USD
5 years ago
Mar 02, 2020
Sell 34.1 K USD
Griffin Deborah A
Chief Accounting Officer
- 2941
11.5989 USD
5 years ago
Mar 03, 2020
Sell 13.3 K USD
Griffin Deborah A
Chief Accounting Officer
- 1166
11.3658 USD
5 years ago
Feb 19, 2020
Sell 100 K USD
Drape Eric
Executive VP Global Operations
- 8000
12.51 USD
5 years ago
Feb 14, 2020
Sell 159 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 13090
12.1422 USD
5 years ago
Feb 14, 2020
Sell 47.7 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 3926
12.1422 USD
5 years ago
Feb 13, 2020
Sell 940 K USD
Sabag Mark
See "Remarks" below
- 72130.5421
13.0286 USD
5 years ago
Feb 14, 2020
Sell 32.1 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 2647
12.1422 USD
5 years ago
Feb 14, 2020
Sell 107 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 8825
12.1422 USD
5 years ago
Feb 14, 2020
Sell 76 K USD
Drape Eric
Executive VP Global Operations
- 6262
12.1357 USD
5 years ago
Feb 14, 2020
Sell 22.8 K USD
Drape Eric
Executive VP Global Operations
- 1878
12.1357 USD
5 years ago
Feb 10, 2020
Sell 153 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 12538
12.2405 USD
5 years ago
Feb 10, 2020
Sell 58.9 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 4799
12.27 USD
5 years ago
Feb 10, 2020
Sell 50.9 K USD
Nazzi Gianfranco
EVP, Growth Markets Commercial
- 4155
12.2417 USD
5 years ago
Feb 10, 2020
Sell 68 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 5544
12.27 USD
5 years ago
Feb 10, 2020
Sell 38.5 K USD
Drape Eric
Executive VP Global Operations
- 3144
12.2417 USD
5 years ago
Feb 10, 2020
Sell 69.6 K USD
Dethlefs Sven
EVP Global Marketing&Portfolio
- 5669
12.27 USD
5 years ago
Feb 10, 2020
Sell 75.9 K USD
Daniell Richard
Exec. VP, European Commercial
- 6199
12.2417 USD
5 years ago
Dec 31, 2019
Sell 24.4 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 2459
9.9212 USD
5 years ago
Dec 02, 2019
Sell 45.2 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 4310
10.4906 USD
5 years ago
Nov 05, 2019
Sell 2.14 K USD
McClellan Michael James
EVP, Chief Financial Officer
- 242
8.8341 USD
5 years ago
Sep 18, 2019
Sell 3.87 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 494
7.8313 USD
5 years ago
Sep 18, 2019
Sell 7.52 K USD
Nazzi Gianfranco
EVP, Growth Markets Commercial
- 962
7.8203 USD
5 years ago
Sep 18, 2019
Sell 11 K USD
McClellan Michael James
EVP, Chief Financial Officer
- 1406
7.8313 USD
5 years ago
Sep 18, 2019
Sell 18.6 K USD
Griffin Deborah A
Chief Accounting Officer
- 2376
7.8313 USD
5 years ago
Sep 18, 2019
Sell 9.2 K USD
Daniell Richard
Exec. VP, European Commercial
- 1176
7.8203 USD
5 years ago
Sep 09, 2019
Sell 2.38 K USD
Daniell Richard
Exec. VP, European Commercial
- 333
7.16 USD
5 years ago
Jun 04, 2019
Bought 1 M USD
BARER SOL J
Director
+ 104500
9.602 USD
5 years ago
Jun 03, 2019
Bought 997 K USD
BARER SOL J
Director
+ 111000
8.9821 USD
5 years ago
May 20, 2019
Sell 184 K USD
de Notaristefani Carlo
Executive VP Global Operations
- 16070
11.42 USD
5 years ago
May 16, 2019
Sell 7.4 K USD
de Notaristefani Carlo
Executive VP Global Operations
- 629
11.76 USD
5 years ago
Mar 18, 2019
Sell 19.6 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 1179
16.6251 USD
5 years ago
Mar 18, 2019
Sell 5.33 K USD
Nazzi Gianfranco
EVP, Growth Markets Commercial
- 320
16.6446 USD
5 years ago
Mar 18, 2019
Sell 21.6 K USD
Daniell Richard
Exec. VP, European Commercial
- 1297
16.6446 USD
5 years ago
Mar 18, 2019
Sell 38.7 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 2358
16.43 USD
5 years ago
Mar 18, 2019
Sell 3.82 K USD
McClellan Michael James
EVP, Chief Financial Officer
- 230
16.6251 USD
5 years ago
Mar 18, 2019
Sell 15.7 K USD
Griffin Deborah A
Chief Accounting Officer
- 943
16.6251 USD
5 years ago
Mar 18, 2019
Sell 4.37 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 263
16.6251 USD
5 years ago
Mar 18, 2019
Sell 1.55 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 93
16.6251 USD
5 years ago
Mar 18, 2019
Sell 10.5 K USD
Dethlefs Sven
EVP Global Marketing&Portfolio
- 632
16.6251 USD
5 years ago
Mar 12, 2019
Sell 38.7 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 2444
15.82 USD
5 years ago
Mar 12, 2019
Sell 11.6 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 738
15.6749 USD
5 years ago
Mar 12, 2019
Sell 5.1 K USD
Nazzi Gianfranco
EVP, Growth Markets Commercial
- 325
15.6898 USD
5 years ago
Mar 12, 2019
Sell 14.9 K USD
Griffin Deborah A
Chief Accounting Officer
- 953
15.6749 USD
5 years ago
Mar 12, 2019
Sell 10.1 K USD
Dethlefs Sven
EVP Global Marketing&Portfolio
- 647
15.6749 USD
5 years ago
Mar 12, 2019
Sell 11.2 K USD
Daniell Richard
Exec. VP, European Commercial
- 715
15.6898 USD
6 years ago
Mar 04, 2019
Sell 8.64 K USD
Nazzi Gianfranco
EVP, Growth Markets Commercial
- 512
16.8844 USD
6 years ago
Mar 04, 2019
Sell 19.7 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 1166
16.8833 USD
6 years ago
Mar 04, 2019
Sell 6.13 K USD
McClellan Michael James
EVP, Chief Financial Officer
- 363
16.8833 USD
6 years ago
Mar 04, 2019
Sell 49.7 K USD
Griffin Deborah A
Chief Accounting Officer
- 2941
16.8833 USD
6 years ago
Mar 04, 2019
Sell 19.7 K USD
Griffin Deborah A
Chief Accounting Officer
- 1166
16.8833 USD
6 years ago
Mar 04, 2019
Sell 6.91 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 409
16.8833 USD
6 years ago
Mar 04, 2019
Sell 10.2 K USD
Dethlefs Sven
EVP Global Marketing&Portfolio
- 606
16.8833 USD
6 years ago
Mar 04, 2019
Sell 35.4 K USD
Daniell Richard
Exec. VP, European Commercial
- 2098
16.8844 USD
6 years ago
Feb 14, 2019
Sell 69.6 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 3926
17.74 USD
6 years ago
Feb 14, 2019
Sell 32.5 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 1841
17.669 USD
6 years ago
Feb 14, 2019
Sell 56.4 K USD
de Notaristefani Carlo
Executive VP Global Operations
- 3192
17.669 USD
6 years ago
Feb 13, 2019
Sell 90.1 K USD
de Notaristefani Carlo
Executive VP Global Operations
- 5041
17.875 USD
6 years ago
Jan 02, 2019
Sell 25.8 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 1643
15.7025 USD
6 years ago
Nov 30, 2018
Sell 20.3 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 933
21.7621 USD
6 years ago
Nov 05, 2018
Sell 7.87 K USD
McClellan Michael James
EVP, Chief Financial Officer
- 346
22.7316 USD
6 years ago
Sep 18, 2018
Sell 29.4 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 1241
23.707 USD
6 years ago
Sep 18, 2018
Sell 32.7 K USD
Nazzi Gianfranco
EVP, Growth Markets Commercial
- 1379
23.691 USD
6 years ago
Sep 18, 2018
Sell 56.3 K USD
Griffin Deborah A
Chief Accounting Officer
- 2376
23.707 USD
6 years ago
Sep 18, 2018
Sell 14.8 K USD
Dethlefs Sven
EVP Global Marketing&Portfolio
- 625
23.707 USD
6 years ago
Sep 18, 2018
Sell 58.9 K USD
Daniell Richard
Exec. VP, European Commercial
- 2488
23.691 USD
6 years ago
Sep 10, 2018
Sell 14.8 K USD
Daniell Richard
Exec. VP, European Commercial
- 696
21.2502 USD
6 years ago
Aug 09, 2018
Sell 94.5 K USD
Codner Iris Beck
EVP Global Brand&Communication
- 4165
22.699 USD
6 years ago
Aug 03, 2018
Bought 43.8 K USD
Dethlefs Sven
EVP Global Marketing&Portfolio
+ 2000
21.92 USD
6 years ago
May 10, 2018
Bought 4.83 M USD
MIGNONE ROBERTO
Director
+ 250000
19.3188 USD
6 years ago
May 09, 2018
Bought 9.6 M USD
MIGNONE ROBERTO
Director
+ 500000
19.2063 USD
6 years ago
Mar 19, 2018
Sell 43.3 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 2358
18.38 USD
6 years ago
Mar 19, 2018
Sell 21.1 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 1179
17.878 USD
6 years ago
Mar 19, 2018
Sell 8.18 K USD
Nazzi Gianfranco
EVP, Growth Markets Commercial
- 457
17.892 USD
6 years ago
Mar 19, 2018
Sell 5.13 K USD
McClellan Michael James
EVP, Chief Financial Officer
- 287
17.878 USD
6 years ago
Mar 19, 2018
Sell 16.9 K USD
Griffin Deborah A
Chief Accounting Officer
- 943
17.878 USD
6 years ago
Mar 19, 2018
Sell 4.59 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 257
17.878 USD
6 years ago
Mar 19, 2018
Sell 1.63 K USD
Fridriksdottir Hafrun
Executive VP, Global R&D
- 91
17.878 USD
6 years ago
Mar 19, 2018
Sell 10.2 K USD
Dethlefs Sven
EVP Global Marketing&Portfolio
- 571
17.878 USD
6 years ago
Mar 19, 2018
Sell 23.2 K USD
Daniell Richard
Exec. VP, European Commercial
- 1297
17.892 USD
6 years ago
Mar 12, 2018
Sell 46.9 K USD
Stark David Matthew
Exec. VP Chief Legal Officer
- 2441
19.2 USD
6 years ago
Mar 12, 2018
Sell 14.4 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 738
19.489 USD
6 years ago
Mar 12, 2018
Sell 8.99 K USD
Nazzi Gianfranco
EVP, Growth Markets Commercial
- 461
19.498 USD
6 years ago
Mar 12, 2018
Sell 18.6 K USD
Griffin Deborah A
Chief Accounting Officer
- 952
19.489 USD
6 years ago
Mar 12, 2018
Sell 11.2 K USD
Dethlefs Sven
EVP Global Marketing&Portfolio
- 576
19.489 USD
6 years ago
Mar 12, 2018
Sell 13.9 K USD
Daniell Richard
Exec. VP, European Commercial
- 714
19.498 USD
7 years ago
Mar 05, 2018
Sell 13.7 K USD
O'Grady Brendan P.
EVP, North America Commercial
- 705
19.38 USD
7 years ago
Mar 05, 2018
Sell 15 K USD
Griffin Deborah A
Chief Accounting Officer
- 773
19.38 USD
7 years ago
Mar 05, 2018
Sell 21.4 K USD
Daniell Richard
Exec. VP, European Commercial
- 1108
19.28 USD
7 years ago
Feb 14, 2018
Sell 37.8 K USD
Sabag Mark
EVP, Global Human Resources
- 2050
18.45 USD
7 years ago
Feb 15, 2018
Sell 61.6 K USD
Sabag Mark
EVP, Global Human Resources
- 3000
20.52 USD
7. News
Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States. reuters.com - 1 week ago
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. PARSIPPANY, N.J. and REYKJAVÍK, Iceland, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced the availability of SELARSDI™ (ustekinumab-aekn) injection in the U.S., a biosimilar to Stelara® (ustekinumab), for the treatment of psoriatic arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, pediatric plaque psoriasis and pediatric psoriatic arthritis. This is the second biosimilar now available in the U.S. market under the Teva and Alvotech strategic partnership. The FDA has provisionally determined that SELARSDI will be interchangeable with the reference biologic Stelara®, following the expiration of exclusivity for the first interchangeable biosimilar, on April 30, 2025. globenewswire.com - 1 week ago
Billionaire Stanley Druckenmiller Dumped Duquesne's Entire Stake in Broadcom and Bought One of Wall Street's Hottest Drug Stocks Hand Over Fist Though earnings season -- the roughly six-week period each quarter where a majority of S&P 500 companies reveal their latest operating results -- provides plenty of juicy data for investors to sift through, there's arguably no data release more important than quarterly filed Form 13F filings with the Securities and Exchange Commission. fool.com - 1 week ago
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO) TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live webcast at 8 am E.T. on Monday, February 24, 2025. During the conference call, Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer, and external IBD key opinion leaders (KOLs) will discuss new data presented for duvakitug (anti-TL1A) positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organization (ECCO). globenewswire.com - 1 week ago
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea Teva Pharmaceutical Industries (TEVA) and partner Alvotech (ALVO) said the Food and Drug Administration (FDA) agreed to review their AVTO6 treatment for eye disorders. investopedia.com - 1 week ago
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept), a biologic used to treat eye disorders, including diseases which can lead to vision loss or blindness. The process to obtain regulatory approval is anticipated to be completed in the fourth quarter of 2025. globenewswire.com - 1 week ago
Teva Pharm CEO calls for faster US generic drug approvals U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding freezes, the CEO of Israel's Teva Pharmaceutical Industries said on Monday. reuters.com - 2 weeks ago
Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's Auvelity and Sunosi are crucial, with Auvelity expected to generate over 75% of 2025 revenues; as such, today's news is a significant win. Despite high competition in MDD and other markets, Axsome's pipeline, including AXS-07 and AXS-12, shows potential for substantial revenue growth. seekingalpha.com - 2 weeks ago
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' On Monday, Axsome Therapeutics, Inc. AXSM signed a settlement agreement with Teva Pharmaceuticals Inc TEVA. benzinga.com - 3 weeks ago
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): ACCESS HERE THE FULL PRESS RELEASE. businesswire.com - 3 weeks ago
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now Teva Pharmaceuticals Industries Ltd NYSE: TEVA is the world's largest generic drug maker, with over 500 generic and biosimilar treatments in its broad portfolio. The medical sector giant also has a line of branded drugs driving growth. marketbeat.com - 4 weeks ago
Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be outperformed, and a desirable entry point for long-term investors. Teva Pharmaceutical's pipeline, including Duvakitug and multiple biosimilars, offers significant growth prospects, with several key Phase 3 milestones and potential launches from 2025 to 2027. seekingalpha.com - 1 month ago
8. Profile Summary

Teva Pharmaceutical Industries Limited TEVA

image
COUNTRY IL
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 18.6 B
Dividend Yield 0.00%
Description Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Contact 124 Dvora Hanevi'a Street, Tel Aviv, 6944020 https://www.tevapharm.com
IPO Date Feb. 16, 1982
Employees 33892
Officers Mr. Eliyahu Sharon Kalif Executive Vice President & Chief Financial Officer Mr. David R. Mcavoy J.D. Executive Vice President & Chief Legal Officer Mr. Mark Sabag Executive Vice President of International Markets Commercial Mr. Richard Gordon Daniell Executive Vice President of European Commercial Mr. Matthew Shields Executive Vice President of Global Operations Mr. Christopher J. Stevo CFA Senior Vice President of Investor Relations & Competitive Intelligence Kathleen Veit Senior Vice President, Global Compliance & Ethics Officer Mr. Placid Jover Executive Vice President & CHRO Mr. Richard D. Francis President, Chief Executive Officer & Director Mr. Amir Weiss Senior Vice President & Chief Accounting Officer